__timestamp | Lantheus Holdings, Inc. | Perrigo Company plc |
---|---|---|
Wednesday, January 1, 2014 | 176081000 | 2613100000 |
Thursday, January 1, 2015 | 157939000 | 2891500000 |
Friday, January 1, 2016 | 164073000 | 3228800000 |
Sunday, January 1, 2017 | 169243000 | 2966700000 |
Monday, January 1, 2018 | 168489000 | 2900200000 |
Tuesday, January 1, 2019 | 172526000 | 3064100000 |
Wednesday, January 1, 2020 | 200649000 | 3248100000 |
Friday, January 1, 2021 | 237513000 | 2722500000 |
Saturday, January 1, 2022 | 353358000 | 2996200000 |
Sunday, January 1, 2023 | 586886000 | 2975200000 |
In the ever-evolving landscape of the healthcare industry, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for Lantheus Holdings, Inc. and Perrigo Company plc from 2014 to 2023. Over this period, Lantheus Holdings has demonstrated a remarkable increase in cost efficiency, with its cost of revenue surging by approximately 233%, from $176 million in 2014 to $587 million in 2023. In contrast, Perrigo Company plc has maintained a relatively stable cost of revenue, fluctuating around the $3 billion mark, with a slight increase of about 14% over the same period.
This comparison highlights Lantheus Holdings' aggressive growth strategy, while Perrigo's steady approach underscores its focus on maintaining consistent operational costs. As the healthcare sector continues to expand, understanding these cost dynamics is crucial for investors and stakeholders aiming to make informed decisions.
Cost of Revenue Comparison: Sanofi vs Lantheus Holdings, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Analyzing Cost of Revenue: Viatris Inc. and Lantheus Holdings, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Lantheus Holdings, Inc.
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Cost of Revenue: Key Insights for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Lantheus Holdings, Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs MorphoSys AG
Cost of Revenue: Key Insights for Perrigo Company plc and HUTCHMED (China) Limited
Cost of Revenue Comparison: Perrigo Company plc vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.